When: Pullback to 50 SMA ($60.61) with momentum reset

Then: Re-enter 1/3 of trimmed capital

When: Deeper pullback to $57-58 if Eliquis erosion accelerates post-LOE

Then: Deploy final 1/3 reserved capital

SELL (one-third trim with tighter risk parameters)

• Trim one-third of position with stop tightened to 64.90, below the 10 EMA at 65.80 and Bollinger middle at 64.97, vs proposed stop of 65.80 which is only 2.5% below entry
• Re-entry zone reframed as 60.61 (50 SMA) to 62.37 (lower Bollinger Band) with scale-in tranches: 1/3 at 62.50, 1/3 at 60.61, final 1/3 for deeper washout
• Maintain 50% core position through Eliquis patent cliff (late 2026); dividend yield is 3.76% with 2.54x FCF coverage and operating cash flow covers dividend 5x
• Current RSI of 63.55 is below 70 overbought threshold; MACD crossed back above signal line at 1.61 vs 1.57 with histogram +0.04; VWMA at 65.10 with price above it
• TTM P/E of 14.8 and forward P/E of 10.3 reflects known Eliquis discount; revenue stuck at $45-48B range for four years; FCF $12-14B annually for four straight years
• Aggressive analyst's MACD and volume analysis deemed factually incorrect; MACD made fresh highs after pullback from 2.19 to 1.36 in early August
• BMY beta of 0.225 makes it a defensive income vehicle, not a high-beta growth name; sticky inflation and Fed-on-hold regime favors dividend pharma rotation
• Eliquis cliff risk: 16-26% downside, but even 50% Eliquis haircut (aggressive bear case) doesn't vaporize the dividend given structural FCF generation

→ vs aggressive: RSI sequence of 72, 56, 64 is a reset and reload pattern in healthy uptrend, not a textbook topping pattern; current RSI 63.55 is not in overbought territory below the 70 sell signal threshold

→ vs aggressive: MACD claim of flattening is incorrect; MACD crossed back above signal line at 1.61 vs 1.57, histogram turned positive at +0.04, and line is making fresh highs after pullback from 2.19 to 1.36 in early August

→ vs aggressive: Volume claim contradicts VWMA data showing price steadily climbing from 55.33 to 65.10 since July 1, indicating sustained accumulation not distribution

→ vs aggressive: Forward P/E gap of 10.3 vs TTM P/E of 14.8 is a discount for Eliquis cliff, not a trap; cannot count the cliff twice in both compression and erosion arguments

→ vs aggressive: Aggressive analyst treating BMY like a high-beta growth name when it's a 0.225 beta defensive income vehicle

→ vs neutral: Dividend yield of 3.76% collecting on a position with 16-26% downside into patent cliff is a yield trap with countdown timer, not defensive positioning

→ vs neutral: Neutral stance ignores the Eliquis catalyst with a calendar date; it is risk denial not risk management

→ vs neutral: Defensive characteristics justify disciplined entry/exit timing, not inaction in front of known catalyst

HOLD (with tactical one-third trim to ~67% of original position)

• RSI at 63.55 is below the 70 overbought threshold—no bearish divergence present; aggressive analyst reads the chart they want, not what's actually there
• MACD crossed back above signal line at 1.61 vs 1.57 with positive histogram at 0.04 and fresh highs from 1.36—momentum rebuilding, not flattening
• VWMA at 65.10 climbing from 55.33 since July 1 confirms sustained accumulation, not distribution
• Forward P/E of 10.3 anchored to $6.56 forward EPS is a known-risk discount, not a trap; consensus has already incorporated Eliquis concerns
• Beta of 0.225 makes treating BMY as high-beta growth a category error; it is a defensive income vehicle
• Dividend is structurally sound with 2.5x coverage on 12-14B annual FCF—even a 50% Eliquis haircut doesn't break the payout
• Conservative analyst's 50% position through a 16-26% drawdown underestimates catalyst risk despite correct technical and fundamental read
• Conservative analyst's stop at 64.90 is too tight (below 10 EMA at 65.80 and Bollinger middle at 64.97); the original 65.80 stop is more honest
• Re-entry zone of 60.61 to 62.50 makes sense, but must acknowledge 200 SMA at 56.34 as major support if Eliquis cliff hits harder
• Macro regime (sticky inflation, Fed on hold, low recession odds) supports dividend pharma defensives; gold at 4640 doesn't change the thesis
• Price is 11% above 50 SMA and near upper Bollinger Band—near-term extended by any standard, supporting the trim rationale
• Recommended trim: one-third, leaving two-thirds core position; stop at 65.80; re-entry in 60.61-62.50 zone with explicit acknowledgment of potential 57-58 flush

→ vs aggressive: RSI sequence of 72, 56, 64 is not a textbook topping pattern—RSI peaked at 72.79 and is now at 63.55, below the 70 overbought threshold; bearish divergence requires RSI making a lower high while price makes a higher high

→ vs aggressive: MACD analysis is empirically wrong—line crossed back above signal at 1.61 vs 1.57 with positive histogram at 0.04 and fresh highs after pulling back from 2.19 to 1.36; this is momentum rebuilding

→ vs aggressive: Forward P/E of 10.3 is not a trap but a known-risk discount; the market already knows about Eliquis and the 18% rally proves consensus has incorporated the risk

→ vs aggressive: Dividend vaporization claim is unsupported—2.5x dividend coverage on 12-14B FCF survives even a 50% Eliquis haircut

→ vs aggressive: Macro argument doesn't fit—beta 0.225 means BMY moves a fifth as much as the market; in a risk-off environment with low recession odds, defensive dividend pharma typically outperforms on a relative basis

→ vs conservative: 50% position through a 16-26% drawdown is way too much exposure to a known binary catalyst; the conservative analyst is lulled by the defensive profile into underestimating catalyst risk

→ vs conservative: Stop at 64.90 is too tight—it sits below both the 10 EMA at 65.80 and Bollinger middle at 64.97; a stop should break the thesis, not catch normal pullback wicks; ATR at 1.74 argues for wider breathing room

→ vs conservative: Re-entry plan assumes 50 SMA holds, but 200 SMA at 56.34 is the major support; if Eliquis erosion accelerates, a much deeper washout is possible and the plan needs explicit acknowledgment of that scenario

→ vs conservative: Chart is 'near-term extended' per technical report—price 11% above 50 SMA pressing upper Bollinger Band; one cannot pretend there's no extension just because the trend is technically healthy